KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.

MLA

Loaiza-Bonilla, Arturo, et al. “KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.” Cureus, vol. 8, no. 2, Feb. 2016, p. e478. EBSCOhost, https://doi.org/10.7759/cureus.478.

APA

Loaiza-Bonilla, A., Jensen, C. E., Shroff, S., Furth, E., Bonilla-Reyes, P. A., Deik, A. F., & Morrissette, J. (2016). KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer. Cureus, 8(2), e478. https://doi.org/10.7759/cureus.478

Chicago

Loaiza-Bonilla, Arturo, Christopher E Jensen, Stuti Shroff, Emma Furth, Paula A Bonilla-Reyes, Andres F Deik, and Jennifer Morrissette. 2016. “KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.” Cureus 8 (2): e478. doi:10.7759/cureus.478.